Pharmacological Approaches to Evaluating Drug Regimens to Address Antimicrobial Resistance (R01)

Post Date

April 18th 2013

Application Due Date

July 30th 2013

Funding Opportunity Number

RFA-AI-13-024

CFDA Number(s)

93.855
93.856

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $5500000

• Award Range:

  $None - $None

Grant Description

The purpose of this FOA is to support antimicrobial pharmacokinetic and pharmacodynamic (PK/PD) studies of drug combinations or sequentially administered (sequenced) antimicrobial agents in relevant in vitro and animal models to enhance understanding of the host, drug and microbial factors that contribute to the emergence of antimicrobial drug resistance in clinically relevant pathogens with a goal of minimizing the potential for development of resistance. A secondary objective is to establish partnerships among anti-microbial pharmacologists, microbiologists and animal modelers to bridge the gap between antimicrobial pharmacology and its application to fundamental and translational research for the clinical management of drug resistance.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-024.html